新型及新兴 COVID-19 药物的疗效与安全性：法匹拉韦和地塞米松。
Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.
作者信息
Sood Shivani, Bhatia Gurpreet Kaur, Seth Prachi, Kumar Pawan, Kaur Jagjit, Gupta Vidisha, Punia Sandeep, Tuli Hardeep Singh
机构信息
Department of Biotechnology, Mukand Lal National College, Yamuna Nagar, India.
Department of Physics, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, 133207 India.
出版信息
Curr Pharmacol Rep. 2021;7(2):49-54. doi: 10.1007/s40495-021-00253-w. Epub 2021 Feb 18.
PURPOSE OF REVIEW
The widespread respiratory disease of virus known as severe acute respiratory syndrome-coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world.
RECENT FINDINGS
The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2.
SUMMARY
The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019
综述目的
被称为严重急性呼吸综合征冠状病毒2019（SARS-CoV-2）的广泛传播的病毒性呼吸道疾病已感染200多个国家，并在全球造成大流行和严重破坏。
最新发现
该病毒的基因组被迅速测序，以研究其机制、流行病学、药物和疫苗。研究人员正在研究许多药物和疫苗来治疗和预防SARS-CoV-2。法匹拉韦和地塞米松是重新利用的药物，显示出对SARS-CoV-2的治疗潜力和药物疗效。
总结
本综述描述了法匹拉韦和地塞米松从化学到作用机制以对抗SARS-CoV-2的过程。此外，还总结了潜在的副作用，以研究它们控制2019冠状病毒的潜力
Zotero 插件